Upload
heather-mccoy
View
212
Download
0
Tags:
Embed Size (px)
Citation preview
To Fight EID, Think Global, Act Local
• Our response to Emerging Diseases is considered on a global basis, but implementation is regional– The risk and impact of an EID is unique to a particular
region e.g. AHS in Europe– The need and type of intervention is unique to the region
e.g. FMD– The pathogen itself may have unique properties e.g. PRRS
• Achieving a rapid response requires planning and communication between industry and local and regional governments and regulatory authorities– Time lines to mass production of a vaccine can be
shortened if production and testing systems are already prepared
21/04/23 1
Pfizer Animal Health A Pfizer business
A leading global animal health company
Working to assure a safe, sustainable global food supply from healthy beef and dairy cattle, swine, poultry and fish
Helping dogs, cats and horses live healthierlonger lives
Pfizer Animal Health (PAH)
World leader in discovery, development, and manufacture of veterinary vaccines & medicines
700+ veterinary R&D scientists and specialists worldwide
Diverse portfolio of leading veterinary products & services for livestock & companion animals
Operating in 60+ countries
PAH Leader in Global R&D Investment
R&D Spend in $Millions
8102123
3945
78
103113120
165
200
PAH R&D $300 million +
Source: Vetnosis Income Statement Report, released September 2009
Mon- santoAlpharmaVeto- quinolCEVA J&JMerialI/SPPfizer(2010B)
Elanco Bayer Novartis BIV Virbac
PAH Global R&D Network
LincolnNebraska
Charles CityIowa
ThaneIndia
MelbourneAustralia
OlotSpain
Louvain-la-NeuveBelgium
KalamazooMichigan
SandwichUK
ZaventemBelgium
Complementary Businesses to Provide Total Solutions
Nutrition/Vitamins/Probiotics
Diagnostics
Genetics
BusinessServices
Generics
Tech Services
Innovative products
Aquaculture
Food Safety
PAH core businessPAH recently enteredPAH under evaluation
Rapid Development of H1N1 Vaccine for Swine
Pfizer Animal Health developed a vaccine with USDA supportto protect swine from the U.S. outbreak of the H1N1 virus
First industry partner to receive USDA approval for H1N1 vaccine Developed vaccine in a record 4-month period
Scientific Development Manufacturing Scale-up Commercial Justification Regulatory Approvals
Partnered with a ONE TEAM Approach across PAH and USDA
Prudent risk-taking & innovations Strain selection, parallel efforts in scale-up and clinical studies Manufacture of extensive supplies before market needs were
fully defined, Bioreactor, lyophilization cycle
PAH investment in EID vaccines
• EIDs are an increasing global health issue
• There is an increasing risk for new EIDs in the future:– Increasing global travel– Increasing world food trade– Increasing demand for protein
21/04/23 8
PAH investment in EID vaccines
• Louvain-La-Neuve facility has been identified as Pfizer’s European center of excellence for the development and production of vaccine solutions against emerging infectious diseases
• Offers advanced capabilities in development and production of vaccines both in expertise and equipment
• Is physically close to local and regional governments and regulatory authorities to facilitate frequent interaction and communication
21/04/23 9
Major Innovation in Pork Production
Favorable to animal welfare and the environment
Allows producers to raise pigs using less feed while enhancing meat quality
Avoids infections and complications that can be caused by physical castration
Improvac allows stakeholders across the pork production chain to reap the benefits of natural boar growth
Pfizer Animal Health in China
• Focus on PAH Goals – Working to assure a safe, sustainable global food supply from
health beef and dairy cattle , swine and fish – Help dogs , cats and horses live healthier and longer
• Introduce high quality animal products to local market – Improvac – Improve meat quality – Low dose and long acting antibiotic s - Draxxin and Excede – Low residue pharmaceutics products - Lincomix® Feed
Medication• The only FDA-approved antimicrobial treatment of ileitis and
mycoplasmal pneumonia with a zero-day withdrawal• Develop products fitting local need
– Identified need for local market – Initiate R&D work for local products